Meredith Cook Sells 400 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

Key Points

• Meredith Cook, VP of ANI Pharmaceuticals, sold 400 shares of the company's stock on October 13th for a total of $36,036, reducing her position by 0.53% to 75,674 shares valued at approximately $6.82 million.
• ANI Pharmaceuticals shares traded up 0.1% to reach $88.74 on Tuesday, with a market cap of $1.93 billion and a P/E ratio of -115.25.
• Analyst ratings for ANI Pharmaceuticals are generally positive, with upgrades from multiple firms including JPMorgan Chase & Co., which increased its target price from $95.00 to $115.00.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the firm's stock in a transaction on Monday, October 13th. The stock was sold at an average price of $90.09, for a total value of $36,036.00. Following the sale, the vice president directly owned 75,674 shares of the company's stock, valued at approximately $6,817,470.66. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Meredith Cook also recently made the following trade(s):

• On Friday, September 12th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $98.42, for a total value of $39,368.00.
• On Wednesday, August 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $88.87, for a total value of $35,548.00.

ANI Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ ANIP traded up $0.13 during trading on Tuesday, reaching $88.74. The stock had a trading volume of 180,084 shares, compared to its average volume of 311,740. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $99.50. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The business's 50-day moving average price is $91.55 and its 200-day moving average price is $74.34. The company has a market cap of $1.93 billion, a P/E ratio of -115.25 and a beta of 0.58.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Thursday, June 8th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $64.48 million during the quarter. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ANIP shares. JPMorgan Chase & Co. lifted their target price on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an "overweight" rating in a report on Wednesday, September 24th. Wall Street Zen raised ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. Piper Sandler reaffirmed an "overweight" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, HC Wainwright lifted their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a "buy" rating in a report on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $99.14.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ANIP. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the first quarter worth about $28,000. Caitong International Asset Management Co. Ltd increased its position in shares of ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after purchasing an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. increased its position in shares of ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock worth $39,000 after purchasing an additional 400 shares in the last quarter. State of Wyoming acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $50,000. Finally, National Bank of Canada FI acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at about $79,000. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.